Harpoon Therapeutics reports partial response in early-stage prostate cancer study

 

• Harpoon Therapeutics (HARP +3.7%) has reported a confirmed partial response for its most advanced program, HPN424 in Phase 1/2a study for the treatment of metastatic castration-resistant prostate cancer.
• At the highest fixed dose tested to date, 160ng/kg, one patient out of 7 showed confirmed partial response with tumor lesion reduction of 43%, and 3 of 7 patients have had serum PSA declines from baseline, including one patient with a PSA reduction greater than 50%.
• HPN424 was generally well tolerated and cytokine-related adverse events have been manageable. Severe adverse events include cytokine release syndrome (10%), ALT increase (11%) and AST increase (11%).
• Presentation of Phase 1 data and initiation of an expansion cohort is planned for 1H of 2021. Interim data from this expansion cohort is anticipated by the end of 2021.
• Also, another candidate HPN536 in Phase 1/2a, showed that among the relapsed/refractory ovarian cancer patients, 8 of 12 (67%) patients demonstrated stability of target lesions. HPN536 appears to be well tolerated. One CRS grade 3 occurred in the absence of dexamethasone premedication treatment. Initiation of an expansion cohort is anticipated by 2H of 2021, with data presentation of Phase 1 by year-end 2021.
• https://seekingalpha.com/news/3642620-harpoon-therapeutics-reports-partial-response-from-hpn424-early-stage-study-in-prostate